Last reviewed · How we verify
gemcitabine/carboplatin plus Iniparib
gemcitabine/carboplatin plus Iniparib is a chemotherapy Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Advanced ovarian cancer, Pancreatic cancer.
Gemcitabine and carboplatin work by interfering with DNA replication and cell division, respectively, while iniparib is thought to work by inhibiting PARP enzymes.
Gemcitabine and carboplatin work by interfering with DNA replication and cell division, respectively, while iniparib is thought to work by inhibiting PARP enzymes. Used for Advanced ovarian cancer, Pancreatic cancer.
At a glance
| Generic name | gemcitabine/carboplatin plus Iniparib |
|---|---|
| Sponsor | Sanofi |
| Drug class | chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death in rapidly dividing cells. Carboplatin is a platinum-based chemotherapeutic agent that forms platinum-DNA adducts, causing DNA damage and apoptosis. Iniparib, on the other hand, is a PARP inhibitor that blocks the repair of DNA damage, making cancer cells more susceptible to chemotherapy-induced cell death.
Approved indications
- Advanced ovarian cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Vomiting
- Fatigue
- Diarrhea
- Constipation
Key clinical trials
- Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (PHASE3)
- A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors (PHASE1)
- A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer (PHASE2)
- A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (PHASE2)
- Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (PHASE3)
- A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer (PHASE2)
- A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors (PHASE1)
- Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gemcitabine/carboplatin plus Iniparib CI brief — competitive landscape report
- gemcitabine/carboplatin plus Iniparib updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about gemcitabine/carboplatin plus Iniparib
What is gemcitabine/carboplatin plus Iniparib?
How does gemcitabine/carboplatin plus Iniparib work?
What is gemcitabine/carboplatin plus Iniparib used for?
Who makes gemcitabine/carboplatin plus Iniparib?
What drug class is gemcitabine/carboplatin plus Iniparib in?
What development phase is gemcitabine/carboplatin plus Iniparib in?
What are the side effects of gemcitabine/carboplatin plus Iniparib?
Related
- Drug class: All chemotherapy drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced ovarian cancer
- Indication: Drugs for Pancreatic cancer
- Compare: gemcitabine/carboplatin plus Iniparib vs similar drugs
- Pricing: gemcitabine/carboplatin plus Iniparib cost, discount & access